Archive | Biopharmaceuticals

Rayno Life Science Market Update: CELG, ONXX, XBI Update 1

Sell-off gets worse with S&P down 2%. Moody’s downgrade of banks expected by end of day. Bear market for commodities? ———– We have been at BIO 2012 in Boston over the past week and will provide interesting trends and data from the Meeting by Monday. Global Slowdown Fears: Market off 1.5% at mid-day with the […]

Continue Reading 0

Very Limited ASCO Boost For Biotechnology Stocks – Update 1 PCYC

A Biopharma Stock We Missed-Pharmacyclics (PCYC $38.21) up 9.89% today It is unbelievable that we missed the huge move in PCYC up 157% YTD with a one year range of 7.63 to 38.56. The market cap is $2.63B. The Company has a robust pipeline of products led by Ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor […]

Continue Reading 0

Rayno Life Science Portfolio Gets ASCO Boost With Antibody Drug Conjugates

Antibody Drug Conjugates Make Progress for Cancer Therapy- Immunogen and Seattle Genetics Many of our focus stocks were up today helped by a late day rally that brought the NASDAQ up 0.46% at the close. Major biotechnology ETF’s (IBB,XBI) also recovered with some green by the end of the day.The Rayno Life Science Portfolio was […]

Continue Reading 0

Todays’ Sell-Off Finally Hits Resilient Biotech Stocks

Facebook Hype Effect-Sell MO Stocks? Many of the favorite momentum stocks are being hit with profit taking today including large cap biopharmaceutical stocks. With the NASDAQ down 0.8% at 2850,  we see a lot of countertrends like gold up $39.70 off recent lows to $1576 accompanied by a big rally in silver and other metal stocks […]

Continue Reading 0

Biotech Sector Avoids Nasty Correction and Hits New Highs

Why is the biotechnology sector still strong? Despite all the gloom and doom in the markets over the past 60 days the biotechnology sector has barely flinched and is currently at YTD highs. Bellwether ETFs IBB (126) and XBI ($82.85) are up over 20% YTD after a brief correction in mid-April compared to the S&P […]

Continue Reading 0

Rayno Life Science Update-Macro Rules, Risk Off

Market Off Its Lows Today-Consumer Cyclical and Technology Outperforming Healthcare The market continues to be weak with the NASDAQ entering its 5th day of the sell-off  down 4.29% but the QQQ ($64.29) NASDAQ-100 has recovered from lows today. The ETF IBB ($64.32) has fared better down only 1.92% over five days and still up 18% YTD […]

Continue Reading 0

Market Sell-Off Continues: Biotechs Follow NASDAQ Down 1.56%

The NASDAQ Biotechnology Index IBB ($122.30)  is off 1.5% today and more than 2% off its all time high of $126.65. The first clue to the current sell-off was a CNBC Fast Money Contributor to buy the ETF XBI ($79) earlier in the week at its top of $82. Earlier this week we urged investors […]

Continue Reading 0

Rayno Life Science Portfolio Update: ALR, GPRO, REGN

Consolidation Continues in Mid Cap DX Companies: Bull Market in Biotech Hits New Highs Our Life Science Tools and Diagnostics Portfolio had a nice hit today with GenProbe up 18.75% on the Agreement that it would be sold to Hologic (HOLX $18.82 down 11.2%) for $3.7B or $82.75/sh. This is a strategic deal that builds […]

Continue Reading 0

Biopharmaceuticals Resist Market Correction: M&A du jour Ardea (RDEA)

Biotech Outperforming Tech Lately: M&A Hit of the Day Ardea Biosciences The market continues its choppy trend with the QQQ‘s off  0.9% to $65 with some Internet high fliers like AMZN and NFLX taking a hit. But biotech recovered from earlier losses with the IBB down only 0.35% and surprisingly  Alexion and Regeneron recovered from […]

Continue Reading 0

Rayno Life Science Portfolio: CBST, GILD,HGSI, REGN SQNM

Biotech Rally Ignited By Clinical News and M&A Theme The biotech sector roared back today with major ETF’s IBB ($122) up 2.4% and XBI ($78.6) up 5.1 % driven primarily by Gilead (GILD $52.23) up 12 % and other large caps like Regeneron (REGN $127) up 2.5%. Gilead (GILD) was up on clinical results from their […]

Continue Reading 0